PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
PTC THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$61.53+2.29 (+3.87%)
Close on Oct 19, 2026
- Market cap
- $5.66B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$4.42 (−6.70%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
PTC THERAPEUTICS, INC. saw revenue fall 42.8% to $1.01B over the twelve months to Jun 30, 2026. Operating income fell 82.5% to $125.60M, moving the operating margin from 40.7% to 12.5%. Free cash flow was -$39.78M, down 105.7% from a year earlier.
Revenue
$1.01B
-42.8% vs. a year earlier
Operating income
$125.60M
-82.5% vs. a year earlier
Free cash flow
-$39.78M
-105.7% vs. a year earlier
EPS, diluted
-$0.37
-105.3% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $5.66B
- P/E ratio
- –
- Price to sales
- 5.61
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -0.70%
Fundamentals
- Revenue
- $1.01B
- Net income
- -$38.38M
- EPS, diluted
- -$0.37
- Free cash flow
- -$39.78M
- Book value per share
- -$1.80
- Diluted shares
- 92M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$1.01B-42.8% YoY
Gross profit
–
Operating income
$125.60M-82.5% YoY
Net income
-$38.38M-106.1% YoY
EPS, diluted
-$0.37-105.3% YoY
Free cash flow
-$39.78M-105.7% YoY
Reported periodTrailing twelve months